Comparison between Sudeep Pharma IPO and Wakefit Innovations IPO.
Sudeep Pharma IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Wakefit Innovations IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Sudeep Pharma IPO is up to ₹895.00 Cr whereas the issue size of the Wakefit Innovations IPO is up to ₹1,288.89 Cr. The final issue price of Sudeep Pharma IPO is ₹593.00 per share and of Wakefit Innovations IPO is ₹195.00 per share.
| Sudeep Pharma IPO | Wakefit Innovations IPO | |
|---|---|---|
| Face Value | ₹1 per share | ₹1 per share |
| Issue Price (Lower) | ₹563.00 per share | ₹185.00 per share |
| Issue Price (Upper) | ₹593.00 per share | ₹195.00 per share |
| Issue Price (Final) | ₹593.00 per share | ₹195.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 25 shares | 76 shares |
| Fresh Issue Size | 16,02,023 shares | 1,93,42,461 shares |
| Fresh Issue Size (Amount) | up to ₹95.00 Cr | up to ₹377.18 Cr |
| OFS Issue Size | 1,34,90,726 shares | 4,67,54,405 shares |
| OFS Issue Size (Amount) | up to ₹800.00 Cr | up to ₹911.71 Cr |
| Issue Size Total | 1,50,92,749 shares | 6,60,96,866 shares |
| Issue Size Total (Amount) | up to ₹895.00 Cr | up to ₹1,288.89 Cr |
Sudeep Pharma IPO opens on Nov 21, 2025, while Wakefit Innovations IPO opens on Dec 08, 2025. The closing date of Sudeep Pharma IPO and Wakefit Innovations IPO is Nov 25, 2025, and Dec 10, 2025, respectively.
| Sudeep Pharma IPO | Wakefit Innovations IPO | |
|---|---|---|
| Anchor Bid Date | Nov 20, 2025 | Dec 05, 2025 |
| Issue Open | Nov 21, 2025 | Dec 08, 2025 |
| Issue Close | Nov 25, 2025 | Dec 10, 2025 |
| Basis Of Allotment (Tentative) | Nov 26, 2025 | Dec 11, 2025 |
| Initiation of Refunds (Tentative) | Nov 27, 2025 | Dec 12, 2025 |
| Credit of Share (Tentative) | Nov 27, 2025 | Dec 12, 2025 |
| Listing date (Tentative) | Nov 28, 2025 | Dec 15, 2025 |
| Anchor Lockin End date 1 | Dec 26, 2025 | Jan 09, 2026 |
| Anchor Lockin End date 2 | Feb 24, 2026 | Mar 10, 2026 |
Sudeep Pharma IPO P/E ratio is 47.61, as compared to Wakefit Innovations IPO P/E ratio of -171.29.
| Sudeep Pharma IPO | Wakefit Innovations IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Sudeep Pharma Ltd.'s revenue increased by 10% and profit after tax (PAT) rose by 4% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)Wakefit Innovations Ltd.'s revenue increased by 28% and profit after tax (PAT) dropped by 133% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 89.37 | 43.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 76.15 | 36.83 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 47.61 | -171.29 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹6697.85 Cr. | ₹6373.16 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | -6.58% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | -0.68% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.20 | 0.53 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹12.46 | ₹-1.14 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 27.88% | -6.72% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Sudeep Pharma IPO Retail Individual Investors (RII) are offered 52,82,463 shares while in Wakefit Innovations IPO retail investors are offered 52,82,463 shares. Qualified Institutional Buyers (QIB) are offered 30,18,550 shares in Sudeep Pharma IPO and 1,98,29,061 shares in Wakefit Innovations IPO.
| Sudeep Pharma IPO | Wakefit Innovations IPO | |
|---|---|---|
| Anchor Investor Reservation | 45,27,823 shares | 2,97,43,590 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 30,18,550 shares | 1,98,29,061 shares |
| NII | 22,63,913 shares | 99,14,529 shares |
| RII | 52,82,463 shares | 66,09,686 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 1,50,92,749 shares | 6,60,96,866 shares |
Sudeep Pharma IPO subscribed 93.71x in total, whereas Wakefit Innovations IPO subscribed 2.52x.
| Sudeep Pharma IPO | Wakefit Innovations IPO | |
|---|---|---|
| QIB (times) | 213.08x | 3.04x |
| NII (times) | 116.72x | 1.05x |
| Big NII (times) | 134.91x | 0.88x |
| Small NII (times) | 80.33x | 1.41x |
| RII (times) | 15.65x | 3.17x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 93.71x | 2.52x |
